Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06171243
Other study ID # 210821002
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 17, 2023
Est. completion date December 30, 2025

Study information

Verified date December 2023
Source Pontificia Universidad Catolica de Chile
Contact Maria F Elgueta, MD
Phone 223543414
Email panchielgueta@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Post-herpetic neuralgia (PHN) is the most frequent complications related to herpes zoster, and can persist for months or even years, and require extensive treatment. For this purpose, pharmacological therapies based on tricyclic antidepressants (amitriptyline), central nervous system depressants (pregabalin) and also opioids, have been stablished. However, all the drugs mentioned can cause serious systemic adverse effects that worsen the patient's quality of life. To avoid these complications, topical therapies based on Capsaicin or Lidocaine 5% patches have been developed. However, these treatments have shown dissimilar results in controlling PHN, so a mixed formulation of lidocaine/tetracaine could show better results. For these reasons, the main objective of our work is to evaluate the plasma levels of lidocaine derived from the application of a topical formulation of lidocaine derived from the application of a topical formulation of lidocaine 23%/tetracaine 7% in patients with neuropathic pain.


Description:

The International Association for the Study of Pain (IASP), defines neuropathic pain as "pain caused by injury or pathology of the somatosensory system", which is usually moderate to severe intensity, with a clinical course that can last several years, and that, therefore, can significantly affect the quality of life of the person who suffers from it. Neuropathic pain can have a central or peripheral origin. In the case of peripheric origin, conditions such as diabetic neuropathy, trigeminal neuralgia and post-herpetic neuralgia distinguish, among others. Post-herpetic neuralgia (PHN) is the most frequent complication related to Herpes Zoster, appearing in 10 to 34% of infected patients. It can persist for months, or even years, and require an extensive treatment, which can cause a huge deterioration in the quality of patients life. It is often installed as a debilitating, intense and refractory neuropathic pain to most of the strategies tried, and its treatment is usually a real challenge, since therapeutic alternatives are often exhausted, without the patient being able to obtain real pain relief. Thus, for example, after 1 year, almost 10% of patients persist with PHN, most of them being elderly and generally, fragile. Some of the risk factors described for the appearance of PHN, are the extension, severity and duration of the skin rash, age, severe immunosuppression, a concomitant autoimmune pathology, diabetes, cancer, recent physical trauma and psychological comorbidity, among others. In fragile patients, more than one risk factor is usually associated, increasing the probability of developing PHN. In individuals 85 years old or older, the risk increases to 50%. Regarding to post-herpetic neuralgia´s pathophysiology, it has been defined that herpes zoster can affect both peripheral and central nerves, with two processes that are important in the development of pain: desensitization and deafferentation. Some studies have also shown an increase in the number of voltage-gated sodium channels, alterations in voltage-gated potassium channels, and an increase in the number of TRPV1 receptors in animal models of neuropathic pain. Other mechanisms associated with the development of PHN are related to the loss of GABAergic neurons and increased release of pro-inflammatory mediators in the damaged tissue, such as: substance P, bradykinins, histamine, cytokines and ions (H+ y K+). Considering the pathophysiology of PHN, pharmacological therapies have been established, that aim to relieve pain since the onset of herpes zoster and prevent associated complications. Regarding the use of tricyclic antidepressants for pain management, it has been estimated that they generate a good response in the patient, but with a series of adverse effects, due to their systemic administration, such as: anticholinergic effects (dry mouth, constipation, urinary retention, nausea, blurred vision and orthostatic hypotension), arrhythmias (prolongation of the QT interval, Torsades de Pointes) and sudden death in susceptible patients. On other hand, treatments for PHN based on the administration of drugs that depress the nervous system, such as antiepileptic drugs (pregabalin and gabapentin) or opioids, can cause adverse reactions, such as drowsiness, edema, ataxia and constipation. To avoid these adverse effects, reduce pharmacological interactions and improve adherence to treatment, pharmacological alternatives have been proposed for topical administration based on Capsaicin (TRPV1 agonist) or lidocaine (local anesthetic, sodium channel blocker). Lidocaine is one of the most widely used local anesthetics, in various presentations for topical use, to relieve or prevent pain in dermatological procedures, such as removal of tattoos and skin blemishes, management of burns, among others. In chronic pain, a systematic review that included 12 primary studies, with a total of 508 participants, compared the effectiveness of various topical formulations of lidocaine (5% cream, 5% patch, 5% gel and 8% spray) versus placebo in treating neuropathic pain. Effectiveness was observed, but in a small number of patients. The authors concluded that further studies are needed to determine efficacy and safety of these topical lidocaine preparations in the management of neuropathic pain. Another presentation of 5% lidocaine for the management of neuropathic pain was an "adhesive cream" (or plaster) format. This pharmaceutical form is applied and remains deposited on the skin for 12 hours. Only 3% of the applied lidocaine reaches the plasma, to be later metabolized in the liver, and excreted by the kidneys, with a plasma half-life of 7.6 hours. However, this 5% formulation was not very effective and its cost is very high. Formulations with a higher concentration of local anesthetic could be effective in a greater number of patients, but we do not know the pharmacokinetic behaviour that they could present in a population of elderly patients. Subsequently, and in order to improve the analgesic effect of lidocaine, and also broaden the spectrum of use of this intervention, topical preparations have been developed, that combine lidocaine together with other local anesthetics of ester nature, such as lidocaine/prilocaine and lidocaine/tetracaine. The rationale for this combination is given by the pharmacokinetic characteristics of each compound. The anesthesia produced by lidocaine is rapid and intense. Tetracaine, being more lipophilic than lidocaine, concentrates in the stratum corneum of the epidermis, from where it diffuses slowly, its duration is longer, and its systemic uptake is limited. According to the data obtained in a clinical study with 40 patients, the combination of both anesthetics produces a fast-onset topical anesthesia, but with a mean duration of 11 hours. The systemic absorption of both local anesthetics is related to both application period and the exposed surface area. In this area, there are different studies that support the efficacy, clinical safety and patient satisfaction with the topical use of lidocaine/tetracaine used in short-term dermatological procedures. A study testing higher doses of lidocaine 23%/tetracaine 7% on the face of 52 healthy young subjects and maintained for 2 hours, showed that the plasma concentration of lidocaine remained at safe levels for each subject, and only correlated with some topical adverse reactions, such as local irritation and dermatitis. However, compounds with non-standarized doses, used over time and in excessive application area, can lead to dangerous results. Currently, there are no defined protocols that allow the safe use of mixed topical anesthetic formulations and therefore, the need to create a safe clinical profile is crucial. Based on the information presented previously, we considerate that a topical formulation of 23% lidocaine/7% tetracaine, could be useful for the treatment of post herpetic neuropathy during chronic treatment. However, nothing has been studied about the efficacy in daily use for PHN, nor has its safety profile been evaluated in fragile patients, such as those who develop this clinical condition. For these reasons, it seems important to document, initially, the extension of the systemic absorption of lidocaine after the application of this eutectic mixture of Lidocaine/Tetracaine in patients with neuropathic pain and to correlate these levels with the appearance of adverse effects. The results of this study will allow us to obtain data that will help us prepare a subsequent clinical study, where the efficacy of our formulation will be evaluated versus a standard treatment against post-herpetic neuralgia.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 30, 2025
Est. primary completion date January 4, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Trigeminal neuralgia - Postherpetic neuralgia - Diabetic neuropathy - Chronic postoperative pain - Complex regional pain syndrome - HIV neuropathy - Peripheral neuropathy Exclusion Criteria: - Intravenous lidocaine and/or other treatment interfering with the protocol

Study Design


Intervention

Drug:
Lidocaine topical
Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge: A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period. 10 grams will be applied every 12 hours for a period of 48 hours.

Locations

Country Name City State
Chile Pontificia Universidad Catolica de Chile Santiago Metropolitana

Sponsors (1)

Lead Sponsor Collaborator
Pontificia Universidad Catolica de Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lidocaine plasmatic levels measured by high performance liquid chromatography Lidocaine total dose, after using Lidocaine 23%/Tetracaine 7% formulation.10 grams will be applied every 12 hours for a period of 48 hours.
Time "0", where time "0" corresponds to the moment of application of the cream for the first time.
Group M1 (Sample N1: 30 min, N2: 2 hours, N3: 4 hours, N4: 12 hours, N5: 26 hours) Group M2 (Sample N1: 45 min, N2: 3 hours, N3: 8 hours, N4: 18 hours, N5: 32 hours) Group M3 (Sample N1: 60 min, N2: 4 hours, N3: 12 hours, N4: 24 hours, N5: 38 hours) Group M4 (Sample N1: 90 min, N2: 5 hours, N3: 16 hours, N4: 30 hours, 44 hours)
From first application of the cream, which will be applied every 12 hours, to 48 hours after the first application
Secondary Number of Participants with Blood Pressure adverse reactions Systolic and Diastolic Blood Pressure
Group M1 (Sample N1: 30 min, N2: 2 hours, N3: 4 hours, N4: 12 hours, N5: 26 hours) Group M2 (Sample N1: 45 min, N2: 3 hours, N3: 8 hours, N4: 18 hours, N5: 32 hours) Group M3 (Sample N1: 60 min, N2: 4 hours, N3: 12 hours, N4: 24 hours, N5: 38 hours) Group M4 (Sample N1: 90 min, N2: 5 hours, N3: 16 hours, N4: 30 hours, 44 hours)
From first application of the cream, which will be applied every 12 hours, to 48 hours after the first application
Secondary Number of Participants with appearance of Heart rate adverse reactions Heart rate will be measured:
Group M1 (Sample N1: 30 min, N2: 2 hours, N3: 4 hours, N4: 12 hours, N5: 26 hours) Group M2 (Sample N1: 45 min, N2: 3 hours, N3: 8 hours, N4: 18 hours, N5: 32 hours) Group M3 (Sample N1: 60 min, N2: 4 hours, N3: 12 hours, N4: 24 hours, N5: 38 hours) Group M4 (Sample N1: 90 min, N2: 5 hours, N3: 16 hours, N4: 30 hours, 44 hours)
From first application of the cream, which will be applied every 12 hours, to 48 hours after the first application
Secondary Number of Participants with appearance of Adverse Drug Reactions Appearance of Adverse Drug Reactions, such as
Group M1 (Sample N1: 30 min, N2: 2 hours, N3: 4 hours, N4: 12 hours, N5: 26 hours) Group M2 (Sample N1: 45 min, N2: 3 hours, N3: 8 hours, N4: 18 hours, N5: 32 hours) Group M3 (Sample N1: 60 min, N2: 4 hours, N3: 12 hours, N4: 24 hours, N5: 38 hours) Group M4 (Sample N1: 90 min, N2: 5 hours, N3: 16 hours, N4: 30 hours, N5: 44 hours)
From first application of the cream, which will be applied every 12 hours, to 48 hours after the first application
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4